hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06303583 id: IRB- 2022-213 briefTitle: Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma acronym: CRIS overallStatus: ENROLLING_BY_INVITATION date: 2022-06-01 date: 2024-08-31 date: 2026-12-31 date: 2024-03-12 date: 2024-03-12 name: Qiu Guoqin class: OTHER briefSummary: The purpose of study is to investigate the safety and efficacy of sequential immunotherapy with neoadjuvant chemoradiotherapy for esophageal cancer conditions: Esophageal Squamous Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: paclitaxel name: carboplatin name: tislelizumab name: radiotherapy measure: Complete pathological response rate measure: R0 resection rate measure: 2-year Disease-free survival rate measure: 2-year overall survival rate measure: Safety will be analyzed through the incidence of adverse events, serious adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital city: Hangzhou state: Zhejiang zip: 310000 country: China lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06303570 id: CBL-0202DD briefTitle: A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas overallStatus: NOT_YET_RECRUITING date: 2024-06-28 date: 2025-05-23 date: 2025-05-23 date: 2024-03-12 date: 2024-03-12 name: Caliway Biopharmaceuticals Co., Ltd. class: INDUSTRY briefSummary: This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas. conditions: Dercum's Disease studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: CBL-514 injection name: 0.9% Sodium chloride measure: To estimate the treatment effect, as measured by Complete Response (CR), between CBL-514 and placebo at Week 12 in participants with Dercum's disease (DD). measure: To estimate the treatment effect, as measured by pain, between CBL-514 and placebo at Week 12 in participants with DD. measure: To estimate the treatment effect, as measured by CR, between CBL-514 and placebo, at Weeks 4, 8, 16, 20, and 24. measure: To estimate the treatment effect, as measured by CR, between CBL-514 and placebo, at Weeks 4, 8, 16, 20, and 24. measure: To estimate the treatment effect, as measured by CR, between CBL-514 and placebo, at Weeks 4, 8, 16, 20, and 24. measure: To estimate the treatment effect, as measured by CR, between CBL-514 and placebo, at Weeks 4, 8, 16, 20, and 24. measure: To estimate the treatment effect, as measured by CR, between CBL-514 and placebo, at Weeks 4, 8, 16, 20, and 24. measure: To estimate the treatment effect, as measured by partial response, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To estimate the treatment effect, as measured by partial response, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To estimate the treatment effect, as measured by partial response, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To estimate the treatment effect, as measured by partial response, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To evaluate the treatment effect, as measured by change in volume, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To evaluate the treatment effect, as measured by pain, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To evaluate the treatment effect, as measured by pain, between CBL-514 and placebo, at Weeks 4, 8, 12, 16, 20, and 24. measure: To evaluate the incidence of adverse events of special interests (AESI) as defined in the protocol. measure: To evaluate the incidence of clinically significant abnormal findings as defined in the protocol as defined in the protocol. sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT hasResults: False
nctId: NCT06303557 id: AEŞH-EK1-2023-797 briefTitle: Effect of ESPB on Intraoperative Remifentanil Consumption overallStatus: RECRUITING date: 2024-01-31 date: 2024-11-30 date: 2024-12-30 date: 2024-03-12 date: 2024-03-12 name: Atatürk Chest Diseases and Chest Surgery Training and Research Hospital class: OTHER briefSummary: In recent years, regional anesthesia techniques have also been frequently applied to patients for pain relief. Erector spinae plane block (ESPB), is among the regional anesthesia techniques frequently used in lumbar spine surgery.
General anesthesia (GA) is the main method of anesthesia for lumbar spine surgery. However, GA can only inhibit the projection system of the cortical limbic system or hypothalamic cortex. GA cannot completely block the transmission of peripheral noxious stimulus to the central nervous system and cannot effectively inhibit the intraoperative stress response. With the addition of peripheral blocks such as ESPB, lower remifantanil consumption, and more stable hemodynamics are expected by providing preemptive analgesia in patients.
As a result of all these; it was aimed to compare the intraoperative remifantanil consumption of patients who underwent preoperative ESPB in patients who will undergo lumbar spine surgery resection under GA with those who underwent postoperative ESPB. conditions: Lumbar Spine Surgery conditions: Erector Spinae Plane Block conditions: Remifentanil Consumption studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Preoperative Erector Spinae Plane Block name: Postperative Erector Spinae Plane Block measure: Intraoperative remifentanil consumption measure: Mean arterial pressure measure: Heart rate measure: Pain scores sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Etlik City Hospital status: RECRUITING city: Yenimahalle state: Ankara zip: 06170 country: Turkey name: Musa Zengin, Associate Professor role: CONTACT phone: 00905307716235 email: musazengin@gmail.com name: Deniz Çolak, MD role: CONTACT phone: 00905386519710 email: doctordenizcolak@outlook.com hasResults: False
nctId: NCT06303544 id: R01HL168853 type: NIH link: https://reporter.nih.gov/quickSearch/R01HL168853 briefTitle: More Outside Your Door: A Diet/Physical Activity Intervention to Decrease Risk of Obesity in Alaska Native Preschoolers acronym: MOYD overallStatus: NOT_YET_RECRUITING date: 2024-08-01 date: 2027-06-30 date: 2028-05-30 date: 2024-03-12 date: 2024-03-12 name: Alaska Native Tribal Health Consortium class: OTHER name: Washington State University name: University of Alaska Anchorage briefSummary: The preschool age is a crucial period of growth and an optimal time to begin to establish healthy eating and physical activity habits leading to better food and activity choices into adulthood, thereby minimizing risk for obesity-related diseases and decreasing the cardiometabolic disparities in this Indigenous population. More Outside Your Door is a multi-level, randomized, stepped-wedge intervention trial designed to reduce the disparity of childhood obesity in Yup'ik Alaska Native children by increasing the proportion of nutrient-dense traditional and traditional-like foods offered and increasing physical activity, particularly outdoor activities related to traditional Yup'ik subsistence and lifestyle practices. This 5-year intervention trial targeting 3-5 year olds is conducted in partnership with Rural Action Community Action Program Head Start programs in 12 rural Alaskan communities, where each site is assigned annually to a wedge group to receive either a community-altered culturally-tailored 8-month traditional foods and activities curriculum intervention or the standard regional Head Start program intervention. conditions: Child Obesity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Wedge design using repeated cross sectional samples of Head Start preschool students primaryPurpose: OTHER masking: NONE count: 450 type: ESTIMATED name: Wedge 1 measure: BMI measure: Physical activity measure: Outdoor time measure: Sleep quality measure: Fingernail nitrogen & carbon stable isotope ratios sex: ALL minimumAge: 3 Years maximumAge: 5 Years stdAges: CHILD facility: Alaska Native Tribal Health Consortium city: Anchorage state: Alaska zip: 99508 country: United States lat: 61.21806 lon: -149.90028 hasResults: False
nctId: NCT06303531 id: Efficacious Iron briefTitle: Efficacious Iron for Iron Deficiency Anemia in Adults Aged ≥18 Years overallStatus: ENROLLING_BY_INVITATION date: 2024-02-24 date: 2025-02 date: 2025-02 date: 2024-03-12 date: 2024-03-25 name: Dr. Anil K. Gupta Medicine Professional Corporation class: NETWORK briefSummary: Iron deficiency anemia (IDA) is a widespread condition affecting many people globally. Despite the many cases of IDA, there are few studies that compare the effectiveness of different types of iron supplements with a greater emphasis on the cost of supplements and their tolerability. This study aims to conduct a comparison between different iron supplements to determine the superiority of the iron supplements Ferrous Ascorbate (EBMfer) and Ferrous Fumarate (Eurofer) over polysaccharide iron (FeraMax). This comparison will be conducted by determining the change in hemoglobin levels for participants in this trial over a 3-month period. conditions: Iron Deficiency Anemia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 111 type: ESTIMATED name: Ferrous Fumarate name: Polysaccharide Iron name: Ferrous Ascorbate measure: Change in Hemoglobin Levels measure: Change in Serum Ferritin measure: Tolerability of Study Medication - Discontinuation Rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Albion Finch Medical Centre city: Etobicoke state: Ontario zip: M9V 4B4 country: Canada lat: 43.65421 lon: -79.56711 hasResults: False
nctId: NCT06303518 id: H23-03546 briefTitle: End Tidal Carbon Dioxide Concentration and Depth of Anesthesia in Children overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12-31 date: 2024-12-31 date: 2024-03-12 date: 2024-03-12 name: University of British Columbia class: OTHER briefSummary: Carbon Dioxide (CO2) is a by-product of metabolism and is removed from the body when we breathe out. High levels of CO2 can affect the nervous system and cause us to be sleepy or sedated. Research suggests that high levels of CO2 may benefit patients who are asleep under anesthesia, such as by reducing infection rates, nausea, or recovery from anesthesia . CO2 may also reduce pain signals or the medication required to keep patients asleep during anesthesia; this has not been researched in children.
During general anesthesia, anesthesiologists keep patients asleep with anesthetic gases or by giving medications into a vein. These drugs can depress breathing; therefore, an anesthesiologist will control breathing (ventilation) with an artificial airway such as an endotracheal tube. Changes in ventilation can alter the amount of CO2 removed from the body. The anesthesiologist may also monitor a patient's level of consciousness using a 'Depth of Anesthesia Monitor' such as the Bispectral Index (BIS), which analyzes a patient's brain activity and generates a number to tell the anesthesiologist how asleep they are.
The investigator's study will test if different levels of CO2 during intravenous anesthesia are linked with different levels of sedation or sleepiness in children, as measured by BIS. If so, this could reduce the amount of anesthetic medication the child receives. Other benefits may be decreased medication costs, fewer side effects, and a positive environmental impact by using less disposable anesthesia equipment. conditions: Anesthesia conditions: Hypercapnia conditions: Hypocapnia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The investigators plan to conduct a randomized, prospective, crossover trial. The six arms will be as below:
6. Low Normal ETCO2 -\> Normal ETCO2 -\> High Normal ETCO2 primaryPurpose: OTHER masking: SINGLE maskingDescription: The anesthesiologist will be blinded to the BIS reading and will continue to provide anesthesia according to the protocol. The BIS numerical value in the OR will be covered, but the waveform will be visible to assess signal quality. The anesthesiologist providing care to the patient will not be involved in data collection or analysis whoMasked: CARE_PROVIDER count: 100 type: ESTIMATED name: High normal ETCO2: ETCO2 50 mmHg (+/- 3mmHg) name: Normal ETCO2: ETCO2 40 mmHg (+/- 3mmHg) name: Low Normal ETCO2: ETCO2 30 mmHg (+/- 3mmHg) measure: To determine the effect of end-tidal carbon dioxide concentration (EtCO2) on the depth of anesthesia in children, as measured by BIS. measure: Patient movement as detected clinically by the surgical or anesthetic team. sex: ALL minimumAge: 3 Years maximumAge: 11 Years stdAges: CHILD hasResults: False
nctId: NCT06303505 id: NAPISTAR 1-01 id: 2024-511074-80 type: EUDRACT_NUMBER briefTitle: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC acronym: NAPISTAR1-01 overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-01 date: 2027-01 date: 2024-03-12 date: 2024-03-12 name: Tubulis GmbH class: INDUSTRY briefSummary: The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients receive increasing doses of TUB-040 until the maximal tolerated dose is found. In dose optimization, at least two doses are compared with each other to determine which dose is optimal for patients.
TUB-040 is given IV every 3 weeks until the disease progresses or the patient has to stop due to side effects. conditions: Ovarian Cancer conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: TUB-040 measure: Determination of MTD measure: Maximum plasma/serum concentration (Cmax) measure: Through plasma/serum concentration (Cmin) measure: The time taken to reach the maximum concentration (Tmax) measure: Area Under Curve (AUC) measure: Half life (T1/2) measure: Determination of immunogenicity measure: Determination of efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Christ Hospital city: Cincinnati state: Ohio zip: 45219 country: United States name: Alexander Starodub role: CONTACT name: Alexander Starodub, MD role: PRINCIPAL_INVESTIGATOR lat: 39.12713 lon: -84.51435 hasResults: False
nctId: NCT06303492 id: CTO 4096 briefTitle: Aspiration Risk Assessment by Gastric Ultrasound in eMErgency Surgery and ANesThetic Decision-making: The ARGUMENT Study overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-12 date: 2026-04 date: 2024-03-12 date: 2024-03-12 name: Samuel Lunenfeld Research Institute, Mount Sinai Hospital class: OTHER briefSummary: Pulmonary aspiration of gastric contents is a serious patient safety problem accounting for 50% of anesthesia-related mortality. The risk is higher in patients undergoing emergency surgery as the gastric content is uncertain which poses a challenge to anesthetic decision-making. Standard clinical assessment to identify at-risk patients primarily relies on preoperative fasting guidelines and is not adequate for patients undergoing emergency surgeries. Point-of-care gastric ultrasound (GUS) has emerged as an accurate bedside tool providing information regarding the type and volume of gastric contents. When GUS was added to standard clinical assessment, anesthetic management plan changed in 71% of adult elective and 37% of pediatric emergency surgical procedures. Such data is lacking in adult patients undergoing emergency surgeries. The investigators propose a multicentre mixed-method study to evaluate the impact of GUS on aspiration risk assessment and subsequent Anesthetic Plan before emergency surgeries. The evidence from this study will improve patient safety by accurately identifying patients at risk of aspiration and tailoring anesthetic techniques and airway management to prevent pulmonary aspiration in patients undergoing emergency surgeries. conditions: Pulmonary Aspiration conditions: Emergency Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: DOUBLE whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 142 type: ESTIMATED name: GUS measure: Proportion of change in Anesthetic Plan measure: Percentage change in the three-category risk assessment before and after GUS sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06303479 id: Voldyne_Tele briefTitle: The Effect of Telerehabilitation-Based Respiratory Exercise Programs on Lung Capacity overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-05 date: 2024-09-29 date: 2024-03-12 date: 2024-03-12 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: It is a prospective randomized controlled trial. In this project, it is aimed to examine the effect of telerehabilitation-based instrumental and noninstrumental respiratory exercise program on lung capacities. For this reason;
Socio-demographic data will be questioned by using the Demographic Data Form; participants, age, gender, height, weight, marital status, smoking and alcohol use, presence of disease, whether they are included in a different exercise program, dyspnea, severe nausea and vomiting. The cases will be randomized into two groups: non-instrumented breathing exercises group and instrumented breathing exercises group. The physical activity status of the individuals participating in the study will be questioned using the International Physical Activity Questionnaire-Short Form (IPAQ-SF) at the beginning and end of the study. Pulmonary Function Test (PFT) will be used to measure the lung capacity of the participants.
Instrumented breathing exercises will be performed for 8 weeks, 2 days a week with the telerehabilitation program, 3 days a week as a home program, 5 days a week in total, starting with 1 set of 15 repetitions and the program will progress with progression. Diaphragmatic breathing and thoracic extension exercises will be applied as non-instrumented breathing exercises. For 8 weeks, 2 days a week with telerehabilitation method, 3 days a week as a home program, 5 days a week in total, 1 set of 10 repetitions for each exercise and the program will progress with progression. At the end of 8 weeks, all evaluations of the participants in both groups will be repeated. conditions: Breathing Exercises conditions: Telerehabilitation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 26 type: ESTIMATED name: Non-Instrumental breathing exercise group name: Instrumental breathing exercise group measure: Pulmonary Function Test for FEV1 measure: Pulmonary Function Test for PEF measure: Pulmonary Function Test for FEV1/FVC measure: Pulmonary Function Test for FVC measure: International Physical Activity Questionnaire-Short Form (IPAQ-SF) sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: University of Health Sciences city: Istanbul country: Turkey name: Esra PEHLİVAN, Assoc. Dr. role: CONTACT phone: +90 212 409 02 00 email: esra.pehlivan@sbu.edu.tr name: Esra PEHLİVAN, Assoc. Prof. role: PRINCIPAL_INVESTIGATOR name: Fatma Nur AYYILDIZ, Student role: SUB_INVESTIGATOR name: Beyzanur YEŞİLYURT, Student role: SUB_INVESTIGATOR name: Mustafa ÇÖRTÜK, Prof. Dr. role: SUB_INVESTIGATOR name: Fulya KARAAHMETOĞLU, PhD (c) role: SUB_INVESTIGATOR lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06303466 id: R-23053109 briefTitle: Real World Evidence Study of Danish Fabry Patients acronym: RWE-FABRY overallStatus: ACTIVE_NOT_RECRUITING date: 2023-08-01 date: 2024-08-01 date: 2024-12-31 date: 2024-03-12 date: 2024-03-12 name: Caroline Michaela Kistorp class: OTHER name: Amicus Therapeutics name: Rigshospitalet, Denmark briefSummary: Fabry is a rare X-linked metabolic lysosomal disorder caused by deficiency in the enzyme α-galactosidase A (alpha-Gal A) by mutations in the GLA gene, encoding the alpha-Gal A enzyme, which catalyses glycosphingolipids, namely globotriaosylceramide (Gb3). Reduced or absent alpha-Gal A activity leads to accumulation of Gb3 in various organs as well as cellular dysfunction and inflammation causing phsyical symptoms and eventual organ failure. Treatment has been available since 2001 for Fabry patients - first enzyme replacement therapy and since 2016, an oral chaperone therapy, Migalastat. Although the initial trials of Migalastat had some both short and extended outcome treatment comparisons, the overall evidence of clinical efficacy is based on too small numbers considering the heterogeneity of the Fabry patient population as well as the very slow progression of the disease. Though the body of real-world evidence is growing, there is a need for more publications of real-world long-term data on clinical outcomes with a focus on treatment with Migalastat.